US4460775A
(en)
*
|
1979-08-09 |
1984-07-17 |
Norwich Eaton Pharmaceuticals, Inc. |
2-(3-Mercapto-1-oxopropyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid derivatives
|
US4595675A
(en)
*
|
1979-09-19 |
1986-06-17 |
Hoechst Aktiengesellschaft |
Bicyclic α-iminocarboxylic acid compounds having hypotensive activity
|
US4616031A
(en)
*
|
1979-12-07 |
1986-10-07 |
Adir |
Perhydroindole-2-carboxylic acids as antihypertensives
|
US4644008A
(en)
*
|
1979-12-07 |
1987-02-17 |
Adir |
Perhydroindole-2-carboxylic acids as antihypertensives
|
US4565819A
(en)
*
|
1979-12-07 |
1986-01-21 |
Adir |
Substituted imino diacids, their preparation and pharmaceutical compositions which contain them
|
US4616030A
(en)
*
|
1979-12-07 |
1986-10-07 |
Adir |
Perhydroindole-2-carboxylic acids as antihypertensives
|
US4508729A
(en)
*
|
1979-12-07 |
1985-04-02 |
Adir |
Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
|
FR2503155A2
(fr)
*
|
1980-10-02 |
1982-10-08 |
Science Union & Cie |
Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
|
US4616029A
(en)
*
|
1979-12-07 |
1986-10-07 |
Adir |
Perhydromdole-2-carboxylic acids as antihypertensives
|
DE3177311D1
(de)
*
|
1980-08-30 |
1994-06-09 |
Hoechst Ag |
Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung.
|
ZA817261B
(en)
*
|
1980-10-23 |
1982-09-29 |
Schering Corp |
Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
|
US4532342A
(en)
*
|
1981-02-20 |
1985-07-30 |
Warner-Lambert Company |
N-substituted amino acids as intermediates in the preparation of acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
|
IN156096B
(no)
*
|
1981-03-19 |
1985-05-11 |
Usv Pharma Corp |
|
EP0065301A1
(en)
*
|
1981-05-18 |
1982-11-24 |
Merck & Co. Inc. |
Isoquinoline carboxylic acid derivates, process for preparing and pharmaceutical composition containing the same
|
DE3134933A1
(de)
*
|
1981-09-03 |
1983-03-31 |
Hoechst Ag, 6230 Frankfurt |
"harnstoffderivate, verfahren zu ihrer herstellung und diese enthaltende medikamente sowie deren verwendung"
|
DE3226768A1
(de)
*
|
1981-11-05 |
1983-05-26 |
Hoechst Ag, 6230 Frankfurt |
Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
|
EP0081094A1
(en)
*
|
1981-11-12 |
1983-06-15 |
Merck & Co. Inc. |
Substituted omega-amino-carboxymethyldipeptide antihypertensive agents
|
NZ202903A
(en)
*
|
1981-12-29 |
1988-01-08 |
Hoechst Ag |
1-- pe pyrrol-2-yl-carboxylic acid derivatives and pharmaceutical compositions
|
IE54551B1
(en)
*
|
1982-01-22 |
1989-11-22 |
Ici Plc |
Amide derivatives
|
US4665087A
(en)
*
|
1982-02-22 |
1987-05-12 |
Ciba-Geigy Corporation |
1-(carbamyl, thiocarbamyl, and iminocarbamyl)-indoline derivatives
|
US4483850A
(en)
*
|
1982-05-10 |
1984-11-20 |
Merck & Co., Inc. |
N-Terminal substituted oligopeptide converting enzyme inhibitors
|
US4617291A
(en)
*
|
1982-05-14 |
1986-10-14 |
Mead Johnson & Company |
Angiotensin-converting enzyme inhibiting dipeptide derivatives
|
US4427665A
(en)
|
1982-05-19 |
1984-01-24 |
E. R. Squibb & Sons, Inc. |
Phosphinylalkanoyl substituted imino acids and their use in hypotensive compositions
|
EP0099709A3
(en)
*
|
1982-07-19 |
1985-11-13 |
Imperial Chemical Industries Plc |
Amide derivatives
|
US4500713A
(en)
*
|
1982-09-23 |
1985-02-19 |
Usv Pharmaceutical Corporation |
Therapeutic dipeptides
|
DE3302125A1
(de)
*
|
1983-01-22 |
1984-07-26 |
Boehringer Ingelheim KG, 6507 Ingelheim |
Aminosaeure-derivate, verfahren zu ihrer herstellung und verwendung
|
US4659711A
(en)
*
|
1983-01-31 |
1987-04-21 |
Usv Pharmaceutical Corporation |
1,2,3,4-Tetrahydrophthalazine and hexahydropyridazine compounds for treating hypertension
|
DE3303344A1
(de)
|
1983-02-02 |
1984-08-02 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur herstellung von n-alkylierten aminosaeuren und deren estern
|
GB8311286D0
(en)
*
|
1983-04-26 |
1983-06-02 |
Searle & Co |
Carboxyalkyl peptide derivatives
|
DE3333454A1
(de)
*
|
1983-09-16 |
1985-04-11 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur herstellung von n-alkylierten dipeptiden und deren estern
|
DE3333455A1
(de)
*
|
1983-09-16 |
1985-04-11 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur herstellung n-alkylierter dipeptide und deren estern
|
US4542234A
(en)
*
|
1983-10-06 |
1985-09-17 |
Usv Pharmaceutical Corp. |
Process for the separation of (S,S) diastereoisomers
|
DE3345355A1
(de)
*
|
1983-12-15 |
1985-06-27 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur racematspaltung bicyclischer imino-(alpha)-carbonsaeureester
|
DE3413710A1
(de)
*
|
1984-04-12 |
1985-10-24 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur behandlung der herzinsuffizienz
|
US5684016A
(en)
*
|
1984-04-12 |
1997-11-04 |
Hoechst Aktiengesellschaft |
Method of treating cardiac insufficiency
|
US4584299A
(en)
*
|
1984-05-21 |
1986-04-22 |
Warner-Lambert Company |
Method of treating heart failure and medicaments therefor
|
GB8422165D0
(en)
*
|
1984-09-01 |
1984-10-03 |
Wellcome Found |
Compounds
|
US4692522A
(en)
*
|
1985-04-01 |
1987-09-08 |
Merck & Co., Inc. |
Benzofused lactams useful as cholecystokinin antagonists
|
US4785089A
(en)
*
|
1985-06-13 |
1988-11-15 |
Ciba-Geigy Corporation |
Novel sulfonic acid esters and their preparation
|
US4652668A
(en)
*
|
1985-07-03 |
1987-03-24 |
Biomeasure, Inc. |
Aromatic amino acid derivatives
|
DE3529960A1
(de)
*
|
1985-08-22 |
1987-03-05 |
Boehringer Ingelheim Kg |
Aminosaeure-derivate, verfahren zu ihrer herstellung und verwendung
|
US5231084A
(en)
*
|
1986-03-27 |
1993-07-27 |
Hoechst Aktiengesellschaft |
Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
|
EP0254032A3
(en)
*
|
1986-06-20 |
1990-09-05 |
Schering Corporation |
Neutral metalloendopeptidase inhibitors in the treatment of hypertension
|
EP0566157A1
(en)
|
1986-06-20 |
1993-10-20 |
Schering Corporation |
Neutral metalloendopeptidase inhibitors in the treatment of hypertension
|
US4793998A
(en)
*
|
1986-10-20 |
1988-12-27 |
Warner-Lambert Company |
Stabilized drug compositions
|
US4830853A
(en)
*
|
1986-10-20 |
1989-05-16 |
Warner-Lambert Company |
Drug compositions stabilized against oxidation
|
JP2535001B2
(ja)
*
|
1987-01-13 |
1996-09-18 |
ダイセル化学工業株式会社 |
N−アルキル化アミノ酸エステルの製法
|
US5262436A
(en)
*
|
1987-03-27 |
1993-11-16 |
Schering Corporation |
Acylamino acid antihypertensives in the treatment of congestive heart failure
|
US4761479A
(en)
*
|
1987-03-30 |
1988-08-02 |
Warner-Lambert Company |
Crystalline quinapril and a process for producing the same
|
FR2620700B1
(fr)
*
|
1987-09-17 |
1990-06-01 |
Adir |
Procede de synthese d'alpha amino acides n alkyles et leurs esters. application a la synthese de carboxyalkyl dipeptides
|
FR2620699B1
(fr)
*
|
1987-09-17 |
1990-06-01 |
Adir |
Procede de synthese d'alpha amino acides n alkyles et de leurs esters. application a la synthese de carboxyalkyl dipeptides
|
DE3739690A1
(de)
*
|
1987-11-24 |
1989-06-08 |
Hoechst Ag |
Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
|
US5055588A
(en)
*
|
1988-07-06 |
1991-10-08 |
Daicel Chemical Industries Ltd. |
Process for preparing N-substituted amino acid esters
|
US4912221A
(en)
*
|
1988-10-27 |
1990-03-27 |
Occidental Chemical Corporation |
Chiral 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and precursors and preparation thereof
|
DD284030A5
(de)
|
1988-11-24 |
1990-10-31 |
Hoechst Ag,De |
Verfahren zur herstellung von peptiden mit bradykinin-antagonistischer wirkung
|
ZA902661B
(en)
*
|
1989-04-10 |
1991-01-30 |
Schering Corp |
Mercapto-acyl amino acids
|
AU6880291A
(en)
*
|
1989-11-21 |
1991-06-13 |
Schering Corporation |
Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors
|
US5407960A
(en)
*
|
1989-12-22 |
1995-04-18 |
Schering Corporation |
Mercaptocycloacyl aminoacid endopeptidase inhibitors
|
US5075302A
(en)
*
|
1990-03-09 |
1991-12-24 |
Schering Corporation |
Mercaptoacyl aminolactam endopeptidase inhibitors
|
US6300361B1
(en)
|
1990-07-25 |
2001-10-09 |
Novartis Ag |
Stabilized pharmaceutical compositions comprising acid donors
|
US5173506A
(en)
*
|
1990-08-16 |
1992-12-22 |
Schering Corporation |
N-(mercaptoalkyl)ureas and carbamates
|
TW197945B
(no)
*
|
1990-11-27 |
1993-01-11 |
Hoechst Ag |
|
TW258739B
(no)
*
|
1992-04-04 |
1995-10-01 |
Hoechst Ag |
|
US5972990A
(en)
*
|
1992-04-10 |
1999-10-26 |
Brigham And Women's Hospital, Inc. |
Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
|
US5977160A
(en)
*
|
1992-04-10 |
1999-11-02 |
Brigham And Women's Hospital, Inc. |
Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
|
GB2266529A
(en)
*
|
1992-05-01 |
1993-11-03 |
Merck Sharp & Dohme |
Tetrahydroisoquinoline derivatives
|
US5246943A
(en)
*
|
1992-05-19 |
1993-09-21 |
Warner-Lambert Company |
Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
|
US5236934A
(en)
*
|
1992-08-26 |
1993-08-17 |
E. I. Du Pont De Nemours And Company |
1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
|
US5514801A
(en)
*
|
1992-12-29 |
1996-05-07 |
Monsanto Company |
Cyclic sulfone containing retroviral protease inhibitors
|
DE59607750D1
(de)
*
|
1995-03-13 |
2001-10-31 |
Aventis Pharma Gmbh |
Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
|
FR2746394B1
(fr)
|
1996-03-20 |
1998-05-29 |
Roussel Uclaf |
Nouveaux composes tricycliques, leur procede de preparation, et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
|
ATE212990T1
(de)
|
1996-03-20 |
2002-02-15 |
Hoechst Ag |
Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten
|
DE19612067A1
(de)
*
|
1996-03-27 |
1997-10-02 |
Hoechst Ag |
Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen
|
DE19653647A1
(de)
|
1996-12-20 |
1998-06-25 |
Hoechst Ag |
Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
|
DE19719817A1
(de)
*
|
1997-05-13 |
1998-11-19 |
Hoechst Ag |
Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
|
ES2122941B1
(es)
*
|
1997-05-29 |
1999-07-01 |
Esteve Quimica Sa |
Procedimiento para la obtencion de quinapril clorhidrato y solvatos utiles para el aislamiento y purificacion de quinapril clorhidrato.
|
DE19741235A1
(de)
*
|
1997-09-18 |
1999-03-25 |
Hoechst Marion Roussel De Gmbh |
Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
DE19741873A1
(de)
*
|
1997-09-23 |
1999-03-25 |
Hoechst Marion Roussel De Gmbh |
Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
DE19751251A1
(de)
|
1997-11-19 |
1999-05-20 |
Hoechst Marion Roussel De Gmbh |
Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
|
DE19821483A1
(de)
|
1998-05-14 |
1999-11-18 |
Hoechst Marion Roussel De Gmbh |
Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
CN1144598C
(zh)
*
|
1998-06-05 |
2004-04-07 |
沃尼尔·朗伯公司 |
利用氧化镁稳定的含ace抑制剂的组合物
|
US6538006B1
(en)
|
1998-07-08 |
2003-03-25 |
Pharmacia Corporation |
Retroviral protease inhibitors
|
US6191144B1
(en)
|
1998-08-17 |
2001-02-20 |
Warner-Lambert Company |
Method of using angiotensin converting enzyme inhibitor to stimulate angiogenesis
|
NZ333206A
(en)
|
1998-12-08 |
2000-07-28 |
Bernard Charles Sherman |
Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
|
US6060461A
(en)
*
|
1999-02-08 |
2000-05-09 |
Drake; James Franklin |
Topically applied clotting material
|
US6632830B1
(en)
*
|
1999-04-30 |
2003-10-14 |
Millennium Pharmaceuticals, Inc. |
ACE-2 inhibiting compounds and methods of use thereof
|
US20030113330A1
(en)
*
|
1999-11-08 |
2003-06-19 |
Uhal Bruce D. |
Methods for treating pulmonary fibrosis
|
BR0108077A
(pt)
*
|
2000-02-04 |
2002-10-22 |
Children S Hospital Res Founda |
Processo para reduzir placas ateroscleróticas em um mamìfero, método para tratamento da aterosclerose em um mamìfero, composição, métodos para prover proteìna ou polipeptìdeo hidrolisante de lipìdeo biologicamente ativo ou mistura deles, para células de um mamìfero tendo deficiência na proteìna ou polipeptìdeo hidrolisante de lipìdeo biologicamente ativo , para prover lipase de ácido lisossomal biologicamente ativa para células de um mamìfero tendo deficiência de lipase de ácido lisossomal biologicamente ativa, para prover lipase de ácido lisossoal biologicamente ativa para células de um mamìfero com aterosclerose, para tratamento da doença de wolman em um mamìfero, para tratamento de doença de armazenagem de colesteril éster em um mamìfero, e, para tratamento da aterosclerose em um mamìfero
|
CA2303481A1
(en)
*
|
2000-04-05 |
2001-10-05 |
Bernard Charles Sherman |
Pharmaceutical compositions comprising moexipril magnesium
|
FR2807430B1
(fr)
*
|
2000-04-11 |
2002-05-17 |
Adir |
Nouveau procede de synthese des esters de la n-[(s)-1- carboxybutyl]-(s)-alanine et application a la synthese du perindopril
|
EP1386165B1
(en)
|
2000-12-14 |
2011-11-02 |
The Brigham And Women's Hospital, Inc. |
Inflammatory markers for detection and prevention of diabetes mellitus
|
US20050203169A1
(en)
*
|
2001-08-06 |
2005-09-15 |
Moskowitz David W. |
Methods and compositions for treating diseases associated with excesses in ACE
|
WO2003013434A2
(en)
*
|
2001-08-06 |
2003-02-20 |
Genomed, Llc |
Methods and compositions for treating diseases associated with excesses in ace
|
WO2003043624A1
(en)
*
|
2001-11-16 |
2003-05-30 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
US20030157165A1
(en)
*
|
2002-02-01 |
2003-08-21 |
Sherman Bernard Charles |
Stable saccharide-free tablets comprising a salt of quinapril or moexipril
|
US20030215526A1
(en)
*
|
2002-03-08 |
2003-11-20 |
Scott Stofik |
Stable formulations of angiotensin converting enzyme (ACE) inhibitors
|
PT3072978T
(pt)
|
2002-05-09 |
2018-10-15 |
Brigham & Womens Hospital Inc |
1l1rl-1 como um marcador de doença cardiovascular
|
CA2388475C
(en)
|
2002-05-31 |
2009-12-08 |
Brantford Chemicals Inc. |
Preparation of chiral 1,2,3,4-tetrahydro-6,7-dialkoxy-3-isoquinolinecarboxylic acid and derivatives
|
PL375713A1
(en)
|
2002-08-19 |
2005-12-12 |
Pfizer Products Inc. |
Combination therapy for hyperproliferative diseases
|
US20050101640A1
(en)
*
|
2002-10-16 |
2005-05-12 |
Recordati Ireland Limited |
Lisinopril/lercanidipine combination therapy
|
US20040147566A1
(en)
*
|
2002-10-16 |
2004-07-29 |
Amedeo Leonardi |
Lisinopril/lercanidipine combination therapy
|
US20040110241A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Segal Mark S. |
Materials and methods for monitoring vascular endothelial function
|
WO2004054980A1
(en)
*
|
2002-12-16 |
2004-07-01 |
Lupin Limited |
Crystalline form of quinapril hydrochloride and process for preparing the same
|
US9492388B2
(en)
|
2002-12-20 |
2016-11-15 |
St. James Associates Llc/Faber Research Series |
Coated particles for sustained-release pharmaceutical administration
|
CL2004000366A1
(es)
*
|
2003-02-26 |
2005-01-07 |
Pharmacia Corp Sa Organizada B |
USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
|
CL2004000544A1
(es)
*
|
2003-03-18 |
2005-01-28 |
Pharmacia Corp Sa Organizada B |
Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
|
CL2004000541A1
(es)
*
|
2003-03-31 |
2005-02-04 |
Warner Lambert Co |
Procedimiento de preparacion de clorhidrato de quinapril por reaccion entre una 2,5-dioxo-oxazolidina y un ester terbutilico de una tetrahidro isoquinolina, util como principio activo para tratar la hipertension y la insuficiencia cardiaca congestiva
|
JP4901474B2
(ja)
|
2003-05-30 |
2012-03-21 |
ランバクシー ラボラトリーズ リミテッド |
置換ピロール誘導体
|
US7459474B2
(en)
*
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US6869963B2
(en)
*
|
2003-07-11 |
2005-03-22 |
Sandoz Ag |
Stable pharmaceutical compositions containing an ACE inhibitor
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
EP1663184A2
(en)
|
2003-08-29 |
2006-06-07 |
The Brigham And Women's Hospital, Inc. |
Hydantoin derivatives as inhibitors of cellular necrosis
|
WO2005055810A2
(en)
|
2003-12-05 |
2005-06-23 |
The Cleveland Clinic Foundation |
Risk markers for cardiovascular disease
|
US7273881B2
(en)
|
2004-01-16 |
2007-09-25 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US20050203168A1
(en)
*
|
2004-03-11 |
2005-09-15 |
The Regents Of The University Of Michigan |
Angiotensin converting enzyme inhibitor use for treatment and prevention of gastrointestinal disorders
|
US7803838B2
(en)
*
|
2004-06-04 |
2010-09-28 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
AU2005294165B2
(en)
|
2004-10-06 |
2012-02-02 |
The Brigham And Women's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
CA2596426A1
(en)
*
|
2005-01-31 |
2006-08-10 |
Mylan Laboratories, Inc. |
Pharmaceutical composition comprising hydroxylated nebivolol
|
JP2008545742A
(ja)
|
2005-05-31 |
2008-12-18 |
マイラン ラボラトリーズ インク. |
ネビボロールを含む組成物
|
US7888381B2
(en)
|
2005-06-14 |
2011-02-15 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
|
US20070009591A1
(en)
*
|
2005-07-07 |
2007-01-11 |
Trivedi Jay S |
ACE inhibitor formulation
|
WO2007030375A2
(en)
*
|
2005-09-08 |
2007-03-15 |
Children's Hospital Medical Center |
Lysosomal acid lipase therapy for nafld and related diseases
|
US8080579B2
(en)
*
|
2005-10-03 |
2011-12-20 |
The Regents Of The University Of Michigan |
Compositions and methods for treatment of inflammatory bowel disease
|
US8119358B2
(en)
*
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
WO2007069268A2
(en)
*
|
2005-10-14 |
2007-06-21 |
Sun Pharmaceutical Industries Limited |
A process for the preparation of substantially pure 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
WO2007054896A1
(en)
|
2005-11-08 |
2007-05-18 |
Ranbaxy Laboratories Limited |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US20090186817A1
(en)
|
2006-03-21 |
2009-07-23 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
EP2382975A3
(en)
|
2006-05-09 |
2012-02-29 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
CA2659082A1
(en)
|
2006-06-07 |
2007-12-21 |
Tethys Bioscience, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
CN101143846B
(zh)
*
|
2006-09-12 |
2011-02-02 |
南京新港医药有限公司 |
喹那普利拉的金属盐
|
JP2010508358A
(ja)
|
2006-11-01 |
2010-03-18 |
ブリストル−マイヤーズ スクイブ カンパニー |
グルココルチコイド受容体、AP−1、および/またはNF−κB活性の調節剤、並びにその使用
|
WO2008057862A2
(en)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
|
CN101663262B
(zh)
|
2006-12-01 |
2014-03-26 |
百时美施贵宝公司 |
用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
|
BRPI0810409A2
(pt)
|
2007-04-18 |
2015-02-18 |
Thethys Bioscience Inc |
Biomarcadores relacionados ao diabetes e métodos de uso destes
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
AU2008261102B2
(en)
|
2007-06-04 |
2013-11-28 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
EP2195034A2
(en)
*
|
2007-09-27 |
2010-06-16 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of making and using same
|
AU2008324858A1
(en)
*
|
2007-11-07 |
2009-05-14 |
Janssen Pharmaceutica N.V. |
Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
|
US7828840B2
(en)
*
|
2007-11-15 |
2010-11-09 |
Med Institute, Inc. |
Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
|
WO2009149279A2
(en)
|
2008-06-04 |
2009-12-10 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
GB2462022B
(en)
*
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
|
JP2011525537A
(ja)
|
2008-06-24 |
2011-09-22 |
ブリストル−マイヤーズ スクイブ カンパニー |
グルココルチコイド受容体、AP−1、および/またはNF−κB活性のシクロペンタチオフェン調節剤およびその使用
|
EP3241839B1
(en)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
CA2788571A1
(en)
|
2010-02-01 |
2011-08-04 |
Andrew Redington |
Remote ischemic conditioning for treatment and prevention of restenosis
|
US20110240043A1
(en)
|
2010-03-31 |
2011-10-06 |
The Hospital For Sick Children |
Use of remote ischemic conditioning to improve outcome after myocardial infarction
|
AU2011237461B2
(en)
|
2010-04-08 |
2015-11-26 |
The Hospital For Sick Children |
Use of remote ischemic conditioning for traumatic injury
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
BR112014001283A2
(pt)
|
2011-07-18 |
2017-02-21 |
Critical Care Diagnostics Inc |
métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício
|
RU2570752C2
(ru)
|
2011-08-26 |
2015-12-10 |
Вокхардт Лимитед |
Способы лечения сердечно-сосудистых нарушений
|
CN107674071B
(zh)
|
2012-05-11 |
2021-12-31 |
同步制药公司 |
作为隐花色素调节剂的含有咔唑的磺酰胺类
|
ES2786506T3
(es)
|
2012-08-01 |
2020-10-13 |
Zahra Tavakoli |
Composiciones congeladas fluidas que comprenden un agente terapéutico
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
JP2016514693A
(ja)
|
2013-03-15 |
2016-05-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ハイブリッド型ネクロトーシス阻害剤
|
SG11201507751YA
(en)
|
2013-03-21 |
2015-10-29 |
Eupraxia Pharmaceuticals USA LLC |
Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
|
MX2015014666A
(es)
|
2013-04-17 |
2016-03-01 |
Pfizer |
Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
|
US10011637B2
(en)
|
2013-06-05 |
2018-07-03 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
WO2014202659A1
(en)
|
2013-06-21 |
2014-12-24 |
Sanofi-Aventis Deutschland Gmbh |
Process for the preparation of amides of n-[1-(s)-(ethoxycarbonyl)-3-phenylpropyl]-l-alanine
|
US9593113B2
(en)
|
2013-08-22 |
2017-03-14 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
AU2016343952A1
(en)
|
2015-10-27 |
2018-05-10 |
Eupraxia Pharmaceuticals Inc. |
Sustained release formulations of local anesthetics
|
AU2020209215B2
(en)
|
2019-01-18 |
2023-02-02 |
Astrazeneca Ab |
PCSK9 inhibitors and methods of use thereof
|